Trevi Therapeutics Inc (TRVI)

$3.76 -0.02 (-0.53%)
Market Cap 290.55M
Revenue (ttm) 0.00
Net Income (ttm) -29.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 258,500
Avg Vol 2,030,876
Day's Range N/A - N/A
Shares Out 76.87M
Stochastic %K 34%
Beta 0.87
Analysts Strong Sell
Price Target $9.72

Latest News on TRVI

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Jan 8, 2025, 7:30 AM EST - 9 days ago

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Dec 16, 2024, 7:36 AM EST - 4 weeks ago

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

Dec 12, 2024, 9:47 AM EST - 5 weeks ago

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Dec 12, 2024, 7:30 AM EST - 5 weeks ago

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Dec 3, 2024, 4:05 PM EST - 6 weeks ago

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 7:30 AM EST - 2 months ago

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Trevi Therapeutics, Inc. (TRVI) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 11:54 PM EST - 2 months ago

Trevi Therapeutics, Inc. (TRVI) Q3 2024 Earnings Call Transcript

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 6, 2024, 4:05 PM EST - 2 months ago

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

Oct 30, 2024, 4:05 PM EDT - 2 months ago

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

Oct 21, 2024, 7:30 AM EDT - 3 months ago

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

Oct 15, 2024, 7:30 AM EDT - 3 months ago

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program

Oct 3, 2024, 4:05 PM EDT - 3 months ago

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.

Sep 30, 2024, 5:30 PM EDT - 3 months ago

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024

Sep 26, 2024, 7:30 AM EDT - 4 months ago

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024

Sep 4, 2024, 4:05 PM EDT - 4 months ago

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024

Trevi Therapeutics to Participate in September Investor and Medical Conferences

Aug 28, 2024, 7:30 AM EDT - 5 months ago

Trevi Therapeutics to Participate in September Investor and Medical Conferences

Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 1:28 AM EDT - 5 months ago

Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance

Aug 8, 2024, 4:05 PM EDT - 5 months ago

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance

Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024

Aug 1, 2024, 7:30 AM EDT - 6 months ago

Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024

Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events

Jul 2, 2024, 7:30 AM EDT - 7 months ago

Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events

Trevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call Transcript

May 11, 2024, 1:56 PM EDT - 8 months ago

Trevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call Transcript

Trevi Therapeutics to Participate in Upcoming Conferences

May 9, 2024, 7:30 AM EDT - 9 months ago

Trevi Therapeutics to Participate in Upcoming Conferences

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024, 4:05 PM EDT - 9 months ago

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024

May 1, 2024, 4:05 PM EDT - 9 months ago

Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference

Apr 9, 2024, 7:30 AM EDT - 10 months ago

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference

Trevi Therapeutics to Participate in Upcoming April Events

Apr 4, 2024, 7:30 AM EDT - 10 months ago

Trevi Therapeutics to Participate in Upcoming April Events

Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

Apr 2, 2024, 7:30 AM EDT - 10 months ago

Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 6:21 PM EDT - 10 months ago

Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript

Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates

Mar 20, 2024, 4:05 PM EDT - 10 months ago

Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates

Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024

Mar 13, 2024, 4:05 PM EDT - 11 months ago

Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024

Trevi Therapeutics to Participate in Upcoming March Events

Feb 28, 2024, 7:30 AM EST - 11 months ago

Trevi Therapeutics to Participate in Upcoming March Events

Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 7:30 AM EST - 1 year ago

Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Trevi Therapeutics Provides Business Updates

Jan 4, 2024, 7:30 AM EST - 1 year ago

Trevi Therapeutics Provides Business Updates

Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

Dec 5, 2023, 7:30 AM EST - 1 year ago

Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

Trevi Therapeutics, Inc. (TRVI) Q3 2023 Earnings Call Transcript

Nov 12, 2023, 5:46 AM EST - 1 year ago

Trevi Therapeutics, Inc. (TRVI) Q3 2023 Earnings Call Transcript

Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update

Nov 9, 2023, 4:05 PM EST - 1 year ago

Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update

Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough

Nov 2, 2023, 7:30 AM EDT - 1 year ago

Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough

Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023

Nov 1, 2023, 4:05 PM EDT - 1 year ago

Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023

Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis

Oct 13, 2023, 8:30 AM EDT - 1 year ago

Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis

Trevi Therapeutics to Participate in Upcoming September Events

Sep 6, 2023, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming September Events

Trevi Therapeutics, Inc. (TRVI) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 10:49 PM EDT - 1 year ago

Trevi Therapeutics, Inc. (TRVI) Q2 2023 Earnings Call Transcript

Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update

Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023

Aug 3, 2023, 4:05 PM EDT - 1 year ago

Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023

Trevi Therapeutics to Participate in Upcoming August Events

Aug 1, 2023, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming August Events

Trevi Therapeutics to Participate in Upcoming July Investor Events

Jul 6, 2023, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming July Investor Events

Trevi Therapeutics to Participate in Upcoming June Conferences

May 30, 2023, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming June Conferences

Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence

May 22, 2023, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence

Trevi Therapeutics, Inc. (TRVI) Q1 2023 Earnings Call Transcript

May 11, 2023, 6:42 PM EDT - 1 year ago

Trevi Therapeutics, Inc. (TRVI) Q1 2023 Earnings Call Transcript

Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update

Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023

May 9, 2023, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023